Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flupentixol + multi-acting receptor-targeted antipsychotics
- Development stage
- Unknown
- Lead developer
- Taichung Veterans General Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy involves the adjunctive use of flupentixol (brand name Fute) with multi-acting receptor-targeted antipsychotics (MARTAs) for the treatment of schizophrenia. Flupentixol is a thioxanthene-class antipsychotic that acts as a dopamine D1 and D2 receptor antagonist. MARTAs, such as olanzapine and clozapine, are characterized by their affinity for a wide range of receptors, including dopamine D2, serotonin 5-HT2A, histamine H1, and muscarinic receptors. This specific regimen was investigated by Taichung Veterans General Hospital in a Phase 4 clinical trial (NCT04898270) to evaluate whether adding flupentixol could improve clinical efficacy and reduce metabolic syndrome-related side effects, such as weight gain and poor glycemic control, by allowing for a reduction in the MARTA dosage.
- Brand names
- Fute
- Other names
- flupentixol + MARTAsFute + MARTAs
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)ADRA1A (α1A)DDC (Aromatic L-amino acid decarboxylase)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)HRH1 (Histamine H1 Receptor)CES1 (Liver carboxylesterase 1)mAChR (Muscarinic acetylcholine receptors)
Beyond the preview
Go deeper on flupentixol + multi-acting receptor-targeted antipsychotics.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flupentixol + multi-acting receptor-targeted antipsychotics.